SEARCH

SEARCH BY CITATION

References

  • Andrade DM, Ackerley CA, Minett TS, Teive HA, Bohlega S, Scherer SW, Minassian BA. 2003. Skin biopsy in Lafora disease: genotype–phenotype correlations and diagnostic pitfalls. Neurology 61:16111614.
  • Annesi G, Sofia V, Gambardella A, Candiano IC, Spadafora P, Annesi F, Cutuli N, De Marco EV, Civitelli D, Carrideo S, Tarantino P, Barone R, Zappia M, Quattrone A. 2004. A novel exon 1 mutation in a patient with atypical lafora progressive myoclonus epilepsy seen as childhood-onset cognitive deficit. Epilepsia 45:294295.
  • Baykan B, Striano P, Gianotti S, Bebek N, Gennaro E, Gurses C, Zara F. 2005. Late-onset and slow-progressing Lafora disease in four siblings with EPM2B mutation. Epilepsia 46:16951697.
  • Cardinali S, Canafoglia L, Bertoli S, Franceschetti S, Lanzi G, Tagliabue A, Veggiotti P. 2006. A pilot study of a ketogenic diet in patients with Lafora body disease. Epilepsy Res 69:129134.
  • Chan EM, Ackerley CA, Lohi H, Ianzano L, Cortez MA, Shannon P, Scherer SW, Minassian BA. 2004a. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Hum Mol Genet 13:11171129.
  • Chan EM, Omer S, Ahmed M, Bridges LR, Bennett C, Scherer SW, Minassian BA. 2004b. Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology 63:565567.
  • Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G, Elia M, Ackerley CA, Jovic NJ, Bohlega S, Andermann E, Rouleau GA, Delgado-Escueta AV, Minassian BA, Scherer SW. 2003. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 35:125127.
  • Cheng A, Zhang M, Gentry MS, Worby CA, Dixon JE, Saltiel AR. 2007. A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease. Genes Dev 21:23992409.
  • Delgado-Escueta AV, Ganesh S, Yamakawa K. 2001. Advances in the genetics of progressive myoclonus epilepsy. Am J Med Genet 106:129138.
  • Dubey D, Ganesh S. 2008. Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy. Hum Mol Genet 17:30103020.
  • Fernández-Sánchez ME, Criado-García O, Heath KE, García-Fojeda B, Medraño-Fernández I, Gomez-Garre P, Sanz P, Serratosa JM, Rodríguez de Córdoba S. 2003. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum Mol Genet 12:31613171.
  • Franceschetti S, Gambardella A, Canafoglia L, Striano P, Lohi H, Gennaro E, Ianzano L, Veggiotti P, Sofia V, Biondi R, Striano S, Gellera C, Annesi G, Madia F, Civitelli D, Rocca FE, Quattrone A, Avanzini G, Minassian B, Zara F. 2006. Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia 47:640643.
  • Ganesh S, Agarwala KL, Ueda K, Akagi T, Shoda K, Usui T, Hashikawa T, Osada H, Delgado-Escueta AV, Yamakawa K. 2000. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum Mol Genet 9:22512261.
  • Ganesh S, Delgado-Escueta AV, Sakamoto T, Avila MR, Machado-Salas J, Hoshii Y, Akagi T, Gomi H, Suzuki T, Amano K, Agarwala KL, Hasegawa Y, Bai DS, Ishihara T, Hashikawa T, Itohara S, Cornford EM, Niki H, Yamakawa K. 2002a. Targeted disruption of the EPM2A gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioural response in mice. Hum Mol Genet 11:12511262.
  • Ganesh S, Delgado-Escueta AV, Suzuki T, Francheschetti S, Riggio C, Avanzini G, Rabinowicz A, Bohlega S, Bailey J, Alonso ME, Rasmussen A, Thomson AE, Ochoa A, Prado AJ, Medina MT, Yamakawa K. 2002b. Genotype–phenotype correlations for EPM2A mutations in Lafora' progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype. Hum Mol Genet 11:12631271.
  • Ganesh S, Puri R, Singh S, Mittal S, Dubey D. 2006. Recent advances in the molecular basis of Lafora' progressive myoclonus epilepsy. J Hum Genet 51:18.
  • Ganesh S, Singh S. 2005. Neuronal survival in epilepsy: to die or not to die? J Biosci 30:561566.
  • Ganesh S, Suzuki T, Yamakawa K. 2002c. Alternative splicing modulates subcellular localization of laforin. Biochem Biophys Res Commun 291:11341137.
  • Ganesh S, Tsurutani N, Suzuki T, Hoshii Y, Ishihara T, Delgado-Escueta AV, Yamakawa K. 2004. The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies. Biochem Biophys Res Commun 313:11011109.
  • Ganesh S, Tsurutani N, Suzuki T, Ueda K, Agarwala KL, Osada H, Delgado-Escueta AV, Yamakawa K. 2003. The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain. Hum Mol Genet 12:23592368.
  • Gentry MS, Worby CA, Dixon JE. 2005. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.Proc Natl Acad Sci USA 102:85018506.
  • Gomez-Abad C, Afawi Z, Korczyn AD, Misk A, Shalev SA, Spiegel R, Lerman-Sagie T, Lev D, Kron KL, Gómez-Garre P, Serratosa JM, Berkovic SF. 2007. Founder effect with variable age at onset in Arab families with Lafora disease and EPM2A mutation. Epilepsia 48:10111014.
  • Gómez-Abad C, Gómez-Garre P, Gutiérrez-Delicado E, Saygi S, Michelucci R, Tassinari CA, Rodríguez de Córdoba S, Serratosa JM. 2005. Lafora disease due to EPM2B mutations: a clinical and genetic study. Neurology 64:982986.
  • Gómez-Garre P, Gutiérrez-Delicado E, Gómez-Abad C, Morales-Corraliza J, Villanueva VE, Rodríguez de Córdoba S, Larrauri J, Gutiérrez M, Berciano J, Serratosa JM. 2007. Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora. Neurology 68:13691373.
  • Gómez-Garre P, Sanz Y, Rodríguez De Córdoba SR, Serratosa JM. 2000. Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions. Eur J Hum Genet 8:946954.
  • Ianzano L, Young EJ, Zhao XC, Chan EM, Rodriguez MT, Torrado MV, Scherer SW, Minassian BA. 2004. Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A) causes Lafora progressive myoclonus epilepsy. Hum Mutat 23:170176.
  • Ianzano L, Zhang J, Chan EM, Zhao XC, Lohi H, Scherer SW, Minassian BA. 2005. Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes. Hum Mutat 26:397.
  • Ianzano L, Zhao XC, Minassian BA, Scherer SW. 2003. Identification of a novel protein interacting with laforin, the EPM2A progressive myoclonus epilepsy gene product. Genomics 81:579587.
  • Jurczak MJ, Danos AM, Rehrmann VR, Allison MB, Greenberg CC, Brady MJ. 2007. Transgenic overexpression of protein targeting to glycogen markedly increases adipocytic glycogen storage in mice. Am J Physiol Endocrinol Metab 292:E952E963.
  • Ki CS, Kong SY, Seo DW, Hong SB, Kim HJ, Kim JW. 2003. Two novel mutations in the EPM2A gene in a Korean patient with Lafora's progressive myoclonus epilepsy. J Hum Genet 48:5154.
  • Lafora GR. 1911. Über das corkommen amyloider körperchen im innern der ganglienzellen; zugliech ein zum studium der amyloiden substanz im nervensystem. Virchows Arch Pathol Anat 205:230294.
  • Lafora GR, Glueck B. 1911. Beitrag zur histogpathologie der myoklonischen epilepsie. Z Gesamte Neurol Psychiatr 6:114.
  • Liu Y, Wang Y, Wu C, Liu Y, Zheng P. 2006. Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling. J Biol Chem 281:3476834774.
  • Lohi H, Ianzano L, Zhao XC, Chan EM, Turnbull J, Scherer SW, Ackerley CA, Minassian BA. 2005a. Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum Mol Genet 14:27272736.
  • Lohi H, Turnbull J, Zhao XC, Pullenayegum S, Ianzano L, Yahyaoui M, Mikati MA, Quinn NP, Franceschetti S, Zara F, Minassian BA. 2007. Genetic diagnosis in Lafora disease: genotype–phenotype correlations and diagnostic pitfalls. Neurology 68:9961001.
  • Lohi H, Young EJ, Fitzmaurice SN, Rusbridge C, Chan EM, Vervoort M, Turnbull J, Zhao XC, Ianzano L, Paterson AD, Sutter NB, Ostrander EA, Andre C, Shelton GD, Ackerley CA, Scherer SW, Minassian BA. 2005b. Expanded repeat in canine epilepsy. Science 307:81.
  • Minassian BA, Ianzano L, Delgado-Escueta AV, Scherer SW. 2000a. Identification of new and common mutations in the EPM2A gene in Lafora disease. Neurology 54:488490.
  • Minassian BA, Ianzano L, Meloche M, Andermann E, Rouleau GA, Delgado-Escueta AV, Scherer SW. 2000b. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. Neurology 55:341346.
  • Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, Dunham I, Gardner R, Fong CY, Carpenter S, Jardim L, Satishchandra P, Andermann E, Snead 3rd OC, Lopes-Cendes I, Tsui LC, Delgado-Escueta AV, Rouleau GA, Scherer SW. 1998. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 20:171174.
  • Mittal S, Dubey D, Yamakawa K, Ganesh S. 2007. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum Mol Genet 16:753762.
  • Serratosa JM, Gómez-Garre P, Gallardo ME, Anta B, de Bernabé DB, Lindhout D, Augustijn PB, Tassinari CA, Malafosse RM, Topcu M, Grid D, Dravet C, Berkovic SF, de Córdoba SR. 1999. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet 8:345352.
  • Singh S, Satishchandra P, Shankar SK, Ganesh S. 2008. Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin. Hum Mutat 29:E1E12.
  • Singh S, Sethi I, Francheschetti S, Riggio C, Avanzini G, Yamakawa K, Delgado-Escueta AV, Ganesh S. 2006. Novel NHLRC1 mutations and genotype-phenotype correlations in patients with Lafora's progressive myoclonic epilepsy. J Med Genet 43:e48.
  • Singh S, Suzuki T, Uchiyama A, Kumada S, Moriyama N, Hirose S, Takahashi Y, Sugie H, Mizoguchi K, Inoue Y, Kimura K, Sawaishi Y, Yamakawa K, Ganesh S. 2005. Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population. J Hum Genet 50:347352.
  • Solaz-Fuster MC, Gimeno-Alcañiz JV, Ros S, Fernandez-Sanchez ME, Garcia-Fojeda B, Criado Garcia O, Vilchez D, Dominguez J, Garcia-Rocha M, Sanchez-Piris M, Aguado C, Knecht E, Serratosa J, Guinovart JJ, Sanz P, Rodriguez de Córdoba S. 2008. Regulation of glycogen synthesis by the laforin–malin complex is modulated by the AMP-activated protein kinase pathway. Hum Mol Genet 17:667678.
  • Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN. 2003. Human Gene Mutation Database (HGMD): update. Hum Mutat 21:577581.
  • Striano P, Zara F, Turnbull J, Girard JM, Ackerley CA, Cervasio M, De Rosa G, Del Basso-De Caro ML, Striano S, Minassian BA. 2008. Typical progression of myoclonic epilepsy of the Lafora type: a case report. Nat Clin Pract Neurol 4:106111.
  • Tagliabracci VS, Turnbull J, Wang W, Girard JM, Zhao X, Skurat AV, Delgado-Escueta AV, Minassian BA, Depaoli-Roach AA, Roach PJ. 2007. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc Natl Acad Sci USA 104:1926219266.
  • Trujillo-Tiebas MJ, Fenollar-Cortés M, Gómez-Garré P, Lorda-Sánchez I, Serratosa JM, Ayuso García C. 2007a. Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy. Hum Genet 121:651.
  • Trujillo-Tiebas MJ, Gómez-garré P, Arguirre-Lambán J, Lorda-Sánchez I, Serratosa JM, Ayuso C. 2007b. Gene symbol: EPM2A. Hum Genet 121:289290.
  • Trujillo-Tiebas MJ, Gómez-Garré P, Fenolla-Cortés M, Lorda-Sánchez I, Serratosa JM, Ayuso C. 2007c. Gene symbol: EPM2A. Hum Genet 121:289.
  • Trujillo-Tiebas MJ, Gómez-Garré P, Pérez-González N, Lorda-Sánchez I, Serratosa JM, Ayuso C. 2007d. Gene symbol: EPM2A. Hum Genet 121:290.
  • Turnbull J, Kumar S, Ren ZP, Muralitharan S, Naranian T, Ackerley CA, Minassian BA. 2008. Lafora progressive myoclonus epilepsy: disease course homogeneity in a genetic isolate. J Child Neurol 23:240242.
  • Van Heycop Ten Ham M.W. 1975. Lafora disease, a form of progressive myoclonus epilepsy. In: VinkenPJ, BruynGW, editors. The epilepsies. Handbook of clinical neurology. Vol. 15. Amsterdam: North-Holland. p 382422.
  • Vilchez D, Ros S, Cifuentes D, Pujadas L, Vallès J, García-Fojeda B, Criado-García O, Fernández-Sánchez E, Medraño-Fernández I, Domínguez J, García-Rocha M, Soriano E, Rodríguez de Córdoba S, Guinovart JJ. 2007. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 10:14071413.
  • Wang J, Stuckey JA, Wishart MJ, Dixon JE. 2002. A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. J Biol Chem 277:23772380.
  • Wang W, Lohi H, Skurat AV, DePaoli-Roach AA, Minassian BA, Roach PJ. 2007. Glycogen metabolism in tissues from a mouse model of Lafora disease. Arch Biochem Biophys 457:264269.
  • Wang Y, Liu Y, Wu C, McNally B, Liu Y, Zheng P. 2008. Laforin confers cancer resistance to energy deprivation-induced apoptosis. Cancer Res 68:40394044.
  • Worby CA, Gentry MS, Dixon JE. 2006. Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates. J Biol Chem 281:3041230418.
  • Worby CA, Gentry MS, Dixon JE. 2008. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J Biol Chem 283:40694076.
  • Yokoi S, Nakayama H, Negishi T. 1975. Biochemical studies on tissues from a patient with Lafora disease. Clin Chim Acta 62:415423.